The global atopic dermatitis treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The new product launches with rising FDA approvals are a factor contributing to the growth of the market. Atopic dermatitis (a most common and severe form of eczema) is an inflammatory skin condition that affects nearly 30% of the US population, mostly children and adolescents.
A full Report of Global Atopic Dermatitis Treatment Market at https://www.omrglobal.com/industry-reports/atopic-dermatitis-treatment-market
Pfizer, Inc., Mylan N.V., Bausch Health Companies Inc., Bayer HealthCare AG, Encore Dermatology, Inc., AbbVie Inc., Allergan PLC, GlaxoSmithKline PLC, and so on are the key players operating in the global atopic dermatitis treatment market. These players are actively involved in adopting different growth strategies such as mergers and acquisitions, partnerships, collaboration, and strategic agreements among others to remain competitive in the market place. New product launches and investment in the R&D is the key strategy adopted by the players of the global market to sustain their marketplace.
Request a Free Sample of Global Atopic Dermatitis Treatment Market @ https://www.omrglobal.com/request-sample/atopic-dermatitis-treatment-market
In June 2020, Eli Lily and Company had received positive top-line results from the North American (breeze-ad5) phase 3 study of oral selective JAK inhibitor baricitinib in patients with moderate to severe atopic dermatitis. In October 2019, Dermira, Inc. (fully owned subsidiary of Eli Lily and Company), a biopharmaceutical company had received US FDA approval for Fast Track designation for lebrikizumab, its novel, investigational treatment being evaluated for patients with moderate-to-severe atopic dermatitis. Lebrikizumab is currently being evaluated in two Phase 3 studies, ADvocate 1 and ADvocate 2, to confirm its safety and efficacy in adolescent and adult patients, ages 12 years and older, with moderate-to-severe atopic dermatitis. In March 2018, Sanofi SA received FDA approval for Dupixent (Dupilumab), the first biologic drug approved for patients with moderate-to-severe atopic dermatitis.
Global Atopic Dermatitis Treatment Market Segmentation
By Drug Class
• PDE-4 Inhibitor
• Calcineurin Inhibitors
By Route of Administration
Global Atopic Dermatitis Treatment Market – Segment by Region
• The US
• Rest of Europe
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/atopic-dermatitis-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit https://www.omrglobal.com/
Company Name: Orion Market Research
Contact Person: Mr. AnuragTiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 780-304-0404